When you consider the rising cost of healthcare in America, a major physician shortage, and economic headwinds stirring fear across the field, we can’t afford to not use AI. We shouldn’t be asking ourselves questions of why, but rather, why not. But that begs a new question: Why haven’t we seen the impact, adoption, and value of AI more broadly across clinical research?
The ICH’s updated draft guidelines for planning, designing, conducting, recording, and reporting clinical trials introduce a dynamic, risk-based approach to trial design and create universal standards for data. Understanding these guidelines is critical to designing and executing successful clinical trials.
Over the past 20 years, 98% of Alzheimer’s disease treatment clinical trials have failed. But why? INmune Bio CEO and Chief Medical Officer RJ Tesi, MD explores what he says are the three main reasons why so few AD clinical trials succeed and offers guidance on how to improve the chance of success.
New FDA draft guidelines create a path forward for companies that need time after approval to thoroughly examine a drug’s efficacy and safety for diverse, underrepresented patient populations. Explore why these guidelines are necessary, what they mean for sponsors, and when they will be required.
With the rise of generative AI models like ChatGPT, there come questions of how this technology can be used in industry, especially in healthcare. Microsoft's Dr. Hoifung Poon explains how AI (specifically, large language models) can be used to improve patient care and clinical workflows by making it easier to match patients to trials.
This website uses cookies to ensure you get the best experience on our website. Learn more
